Clinically approved combination immunotherapy: Current status, limitations, and future perspective

Clinically approved combination immunotherapy: Current status, limitations, and future perspective

Immune-checkpoint inhibitor-based combination immunotherapy has become a first-line treatment for several major types of cancer including hepatocellular carcinoma (HCC), renal cell carcinoma, lung cancer, cervical cancer, and gastric cancer. Combination immunotherapy counters several immunosuppressi...

Full description

Bibliographic Details
Main Authors: Ligong Lu, Meixiao Zhan, Xian-Yang Li, Hui Zhang, Danielle J. Dauphars, Jun Jiang, Hua Yin, Shi-You Li, Sheng Luo, Yong Li, You-Wen He
Format: Article
Language:English
Published: Elsevier 2022-01-01
Series:Current Research in Immunology
Subjects:
Combination immunotherapy
First-line therapy
Atezolizumab
Bevacizumab
HCC
Dose
Online Access:http://www.sciencedirect.com/science/article/pii/S2590255522000087

Internet

http://www.sciencedirect.com/science/article/pii/S2590255522000087

Similar Items